Method Development and Degradation Studies to Verify the Stabilization of a Gallium Prodrug of Epinephrine

Abstract

Utilizing the unique and varied properties of metals, such as their redox activity, lability, and net charge, metal-based prodrugs can be designed and optimized for numerous applications. The most prominent usage of metal-based prodrugs has historically been anti-cancer agents, though there have been more recent efforts in the development of theranostic and antimicrobial agents as well. Gallium has promise for extending the scope of metal-based prodrugs, as it has been FDA approved for the treatment of tumors and hypercalcemia. Epinephrine is a compelling target for a gallium-based prodrug as conventional prodrugs are not suitable for the treatment of anaphylactic shock. This is because the prodrugs are inactive during their long half-lives. Additionally, as should mitigate drug degradation from high pH, light, and heat. The development of a novel gallium prodrug of epinephrine establishes the first prodrug treatment of anaphylactic shock, and extends the chemical space of metal-based prodrugs.